アクセス数 : ?
ダウンロード数 : ?
ID 110279
タイトルヨミ
ガン チリョウヤク ト フクサヨウ
タイトル別表記
Adverse effects of anti-cancer drugs
著者
土屋, 浩一郎 徳島大学大学院ヘルスバイオサイエンス研究部薬物機能制御学講座分子生物薬学分野 徳島大学 教育研究者総覧 KAKEN研究者をさがす
大坂, 祐貴 徳島大学大学院ヘルスバイオサイエンス研究部薬物機能制御学講座分子生物薬学分野
堀ノ内, 裕也 徳島大学医学部歯学部附属病院薬剤部 徳島大学 教育研究者総覧
田蒔, 美歩 徳島大学大学院ヘルスバイオサイエンス研究部薬物機能制御学講座分子生物薬学分野
東, 桃代 徳島大学薬学部臨床薬学教育支援室 徳島大学 教育研究者総覧 KAKEN研究者をさがす
キーワード
chemotherapy
side-effect
molecular-targeted agent
資料タイプ
学術雑誌論文
抄録
In Japan, about one-half of population suffers from cancer in their lives, and one-third will die of it. Currently, we have three strategies in the treatment of cancer, i.e., surgical treatment, radiotherapy, and chemotherapy(drug therapy). Most conventional chemotherapeutic drugs work by impairing cell division, resulting in apototic cell death. However, these drugs have potent side-effects including nausea and vomiting, diarrhea and constipation, anemia, hair loss, hemorrhage, immunosupression and myelosuppression, and secondary neoplasms due to disrupt normal cell growth. Some specific anti-cancer drugs are associated with organ-specific toxicities including cardiovascular disease(e.g., doxorubicin)and lung disease(e.g., bleomycin). In addition, anti-cancer drugs are applied to patients with maximum tolerated dose(MTD), side-effects are intolerable to the patients in most cases. In order to improve these unpleasant symptoms, some drugs are approved to cope with the side-effects of chemotherapy(synthetic G-CSF for neutropenia, 5-HT3 inhibitors to block one or more of the signals that cause nausea and vomiting)though, medical staffs should pay attention to these sign of side effects. By the way, recent advances in molecular biology have identified numerous genes and proteins involved in malignant transformation as targets of anticancer therapy. Many moleculartargeted agents are now applied at the bedside. Successful developments of trastuzumab in treating breast cancer, imatinib in chronic myeloid leukemia(CML)and gastrointestinal stromal tumors( GISTs), gefitinib and erlotinib in non-small cell lung cancer, sunitinib in GISTs and renal cell carcinoma(RCC), sorafenib in RCC, and bevacizumab in colorectal cancer, have validated the concept of molecular targeting and raised expectations of patients and oncologists alike. These drugs have high selectivity for tumor cells, provide effective treatment, and produce fewer side effects than are seen with conventional anticancer agents. However, unexpected untoward results may occur during treatment. Special attention will be required.
掲載誌名
四国医学雑誌
ISSN
00373699
cat書誌ID
AN00102041
出版者
徳島医学会
65
3-4
開始ページ
67
終了ページ
73
並び順
67
発行日
2009-08-25
EDB ID
フルテキストファイル
言語
jpn
著者版フラグ
出版社版
部局
薬学系
医学系
病院